NEW YORK – The European Commission on Monday approved Johnson & Johnson's subcutaneous Rybrevant (amivantamab) in two new dosing schedules as a first-line treatment for patients with advanced ...
A pore smaller than one nanometer reads peptide sequences amino acid by amino acid, pinpointing single-site Alzheimer's ...
A refined base-pair editor limits unintended neighboring DNA edits while maintaining strong correction of disease-causing ...
Engineers at the University of Pennsylvania and Rice University have refined a technology for editing individual genetic "base pairs" to a new level of precision, opening the door to safer, more ...
The European Commission (EC) has approved an extension of Johnson & Johnson’s Rybrevant (amivantamab) marketing authorization ...
Subcutaneous (SC) amivantamab reduces administration from hours to minutes, with efficacy and safety consistent with intravenous (IV) amivantamab1,2,3,4,5 SC amivantamab is now authorised across all ...
Johnson & Johnson (NYSE: JNJ) today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation (BTD) for subcutaneous amivantamab and hyaluronidase-lpuj as ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results